肝脏脂肪降低76.4%,Pemvidutide治疗NAFLD2期结果积极 2023年11月13日,Altimmune在2023年美国肝病年会上公布了其在研GLP-1产品Pemvidutide治疗NAFLD的2期临床(NCT05292911)结果:治疗24周后,受试者肝脏脂肪含量(LFC)相对减少量为76.4%,血...
但评估对 GLP-1RAs 治疗的组织学反应的研究数量有限,需要使用组织学终点进行足够持续时间的进一步前瞻性研究,以充分评估 GLP-1RAs 在 NAFLD 管理中的功效。 03 存在的问题 尽管GLP-1RAs 在治疗 NAFLD 方面有益处,但我们也认识到 GLP-1RAs 治疗的不...
非酒精性脂肪性肝病(NAFLD)是指在缺乏脂质累积相关继发原因(包括过度饮酒、致脂质沉积的药物)的情况下,组织学或影像学水平检测到肝脏脂肪变性,可从伴有或不伴有炎症的轻度脂肪变性演变为伴有炎症浸润和肝细胞损伤的脂肪变性。2020年来自不同国家的专家小组将NAFLD重新命名为代谢相关脂肪性肝病(MAFLD),MAFLD通常与肥胖、...
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin ...
1(GLP-1)对非酒精性脂肪性肝病(NAFLD)大鼠肝功能及TLR4/NF-κB信号通路的影响.方法 将45只大鼠随机分成两组,正常饲料喂养15只,高脂饮食喂养30只使其形成NAFLD模型.在第10周,把高脂饲料喂养的28只老鼠随机分成两组,模型对照组(14只)和GLP-1干预组(14只);正常饲料喂养的15只为正常对照组.之后对模型对照组...
including the Fibrosis-4 index, aspartate aminotransferase-to-platelet ratio, and NAFLD fibrosis score. These findings suggest that survodutide has the potential to reduce liver fibrosis and improve liver function in patients with NASH, making it a promising therapeutic option for this complex liver ...
including the Fibrosis-4 index, aspartate aminotransferase-to-platelet ratio, and NAFLD fibrosis score. These findings suggest that survodutide has the potential to reduce liver fibrosis and improve liver function in patients with NASH, making it a promising therapeutic option for this complex liver ...
early management of fat accumulation as well as inflammation has become the mainstream strategy for NASH treatment. This review intends to give an overview of the effects of GLP-1 mimetics on the pathogenesis of NAFLD/NASH and their therapeutic potential. Possible mechanisms of action and current ...
Conversely, liver conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD) can increase the risk of HF due to systemic inflammation, oxidative stress, and metabolic disturbances [34, 35]. MASLD contributes to HFpEF ...
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60. Article PubMed PubMed Central Google Scholar Zhao T, Chen H, Cheng C, Zhang J, Yan Z, Kuang J, Kong F, Li C, Lu Q. Liraglutide protects high-glucose-stimulated fibroblasts by ...